Bone Biologics Corp — fact timeline

Bone Biologics Corp: Amendment to Amended and Restated Certificate of Incorporation to effect a 1-for-6 reverse stock split of common stock (effective 2025-06-10).

“On June 5, 2025, Bone Biologics Corporation (the “Company”) filed a Certificate of Amendment to amend its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware. The Certificate of Amendment effects a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-6 shares, effective as of 12:01 a.m. Eastern Time on June 10, 2025 (the “Reverse Stock Split”).”

Bone Biologics Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 7, 2025, Bone Biologics Corporation (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until October 6, 2025, in which to regain compliance with the minimum bid price req”

Phillip Meikle was appointed as Director at Bone Biologics Corp.

“On October 16, 2024, the Board of Directors (the “Board”) of Bone Biologics Corporation (the “Company”) appointed Phillip Meikle to the Company’s Board.”

Don Hankey resigned as director at Bone Biologics Corp.

“On October 1, 2024, Don Hankey informed Bone Biologics Corporation (the “Company”) of his resignation as a director of the Company effective immediately.”

Bone Biologics Corp entered into Securities Purchase Agreement with certain institutional investors valued at Combined offering price of $2.56 per Share and accompanying Warrant and $2.559 per Pre-Funded Warran (effective 2024-03-04).

“On March 4, 2024, Bone Biologics Corporation (the “Company”) priced a public offering (the “Offering”) of (i) 119,000 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), together with warrants (the “Warrants”) to purchase 119,000 shares of Common Stock at a combined public offering price of $2.56 per Share and accompanying Warrant and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 662,251 shares of Common Stock, together with Warrants to purchase 662,251 shares of Common Stock at a combined public offering price of $2.559 per Pre-Funded Warrant and accompanying Warrant.”

Erick Lucera resigned as Director at Bone Biologics Corp.

“As previously disclosed, Erick Lucera resigned from the Board of Directors on December 27, 2023, effective as of the date Mr. Gagnon was appointed.”

Robert E. Gagnon was appointed as Director at Bone Biologics Corp.

“On January 8, 2024, the Board of Directors of Bone Biologics Corporation (the “Company”) appointed Robert E. Gagnon to the Company’s Board of Directors.”

Erick Lucera resigned as director at Bone Biologics Corp.

“On December 27, 2023 Erick Lucera resigned as a director of the Company, effective upon the appointment of a new director.”

Bone Biologics Corp: Filed Certificate of Amendment to effect a 1-for-8 reverse stock split of common stock, effective December 20, 2023 (effective 2023-12-20).

“On December 14, 2023, Bone Biologics Corporation (the “Company”) filed a Certificate of Amendment to amend its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware. The Certificate of Amendment effects a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-8 shares, effective as of 12:01 a.m. Eastern Time on December 20, 2023 (the “Reverse Stock Split”).”

Bone Biologics Corp shareholders approved Adjournment of Special Meeting to solicit additional votes at the 2023-12-12 meeting.

“The Company’s stockholders approved the adjournment of the Special Meeting from time to time, if necessary or appropriate, including to solicit additional votes in favor of Proposal One if there were not sufficient votes at the time of the Special Meeting to adopt Proposal One and/or to establish a quorum.”

Bone Biologics Corp shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split in a range of 1-for-5 to 1-for-20 at the 2023-12-12 meeting.

“The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s Common Stock in a range of 1-for-5 shares to 1-for-20 shares, at the discretion of the board of directors.”

Bone Biologics Corp entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at a cash fee equal to 7.0% of the aggregate gross proceeds raised in the Offering and a management fee (effective 2023-10-30).

“On October 30, 2023, the Company entered into an engagement agreement (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the exclusive placement agent in connection with the Offering.”

Bone Biologics Corp entered into Purchase Agreement with certain institutional investors valued at 1,139,063 shares of the Company's common stock, $0.001 par value per share, at an offering price of (effective 2023-11-16).

“On November 16, 2023, Bone Biologics Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Registered Direct Offering”), 1,139,063 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at an offering price of $0.64 per Share.”

Bone Biologics Corp: Reduced quorum requirement for stockholder meetings from majority to at least one-third in voting power (effective 2023-10-20).

“On October 20, 2023, the Board of Directors of Bone Biologics Corporation (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws (the “Amendment”). The Amendment, which became effective immediately, reduces the quorum requirement at all meetings of the Company’s stockholders from a majority in voting power of the Company’s common stock issued and outstanding and entitled to vote at the meeting to at least one-third in voting power of the Company’s common stock issued and outstanding and entitled to vote at the meeting.”

Bone Biologics Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 27, 2023, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to comply with the $1.00 per share minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As a result of the imposition of a mandatory Panel Monitor, as previously disclosed on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 19, 2023, the Company is not eligible for a compliance period to regain compliance with the minimum bid price requirement. Acco”

Bone Biologics Corp shareholders approved Approval of First Amendment to 2015 Equity Incentive Plan at the 2023-09-12 meeting.

“The Company’s stockholders approved the First Amendment to the Company’s 2015 Equity Incentive Plan.”

Bone Biologics Corp shareholders approved Ratification of Weinberg & Company, P.A. as independent auditor at the 2023-09-12 meeting.

“The Company’s stockholders ratified the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting firm”

Bone Biologics Corp shareholders approved Frequency of future say-on-pay votes at the 2023-09-12 meeting.

“The Company’s stockholders approved, on an advisory basis, that future say-on-pay votes should occur every year.”

Bone Biologics Corp shareholders approved Advisory vote on executive compensation at the 2023-09-12 meeting.

“The Company’s stockholders approved, on an advisory basis, the Company’s executive compensation.”

Bone Biologics Corp shareholders approved Election of directors at the 2023-09-12 meeting.

“The Company’s stockholders elected the following four director nominees to serve until the date of the next Annual Meeting”